Establishing elevated lipoprotein(a) as a target in calcific aortic valve disease

Completed

• Conditions: heart valve disease; 10046973; aortic stenosis

• Registration Number: NL-OMON50522
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 72

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Adult patients, aged 45-80 years old
- Mild to moderate aortic valve stenosis: on echocardiography, aortic valve maximum velocity is >2.0 m/sec

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Severe aortic valve stenosis
- History of radiotherapy of the thorax
- History of rheumatic fever
- Renal insufficiency, defined as eGFR < 30 ml/min
- Hyperparathyroidism
- Paget*s disease of the bone
- Any other treatment or clininically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Standard contra-indications to PET/CT

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the difference between groups in 18F-NaF uptake in<br /><br>the aortic valve, expressed as tissue-to-background ratio. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- To evaluate the in vitro calcification capacity of plasma Lp(a) from<br /><br>participants</p><br>